CTLA4 and melanoma: CTLA-4 blocking has been shown to enhance priming of responsive T cells41 and in a recent study on blood samples derived from melanoma patients it was shown that anti-CTLA-4 immunotherapy can broaden the range of antigens being targeted by the T-cell repertoire10.